{
  "docId": "019de075-c1ce-7016-922a-ee59c26b52e2",
  "docSlug": "7a9033616f2f52a3ff84a89721dd4a41",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 23,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/22",
  "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2",
  "deckJsonHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2.json",
  "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.75
      },
      "kind": "list",
      "text": "Management Team: 3 approved drugs, significant shareholder value, Russell 2000 inclusion.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4da93e2b-0889-4b03-84a1-ed03b48929b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.41
      },
      "kind": "list",
      "text": "NXP800: Fast Track Designation, Phase 1b study in collaboration with ENGOT/GOG-F.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90656979-83d1-4d66-b7bb-f12e6daa9575",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "list",
      "text": "2023 Milestones: Initiated NXP800 Phase 1b, FDA clearance for NXP900 IND, clinical data presentations.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf225be2-4636-4afa-9f08-2994bfcd4942",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.58
      },
      "kind": "list",
      "text": "NXP900: Highly selective compound, IND cleared.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc3d834e-d86e-464d-b752-66c05eec3e1a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.04,
        "y": 0.14
      },
      "kind": "title",
      "text": "Precision medicine pipeline for serious conditions of unmet medical need in oncology",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41262256-3152-49e3-b492-89414d1f9ebd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "Nuvectis Investment Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35487ebc-2ab0-4f7f-aec4-ea53601c831d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "f5d8a1d2-4dcc-4744-90eb-ce74e1f7c7e5",
      "evidence": "title/headline: Nuvectis Investment Highlights",
      "confidence": 0.9
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "6cc257fc-7155-4711-9d02-07bd242c9e59",
      "evidence": "list/bullet: 2023 Milestones: Initiated NXP800 Phase 1b, FDA clearance for NXP900 IND, clinical data presentations.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 22,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb",
      "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline",
      "position": 0,
      "objective": "Highlight the cost of inaction in oncology",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}